X0306 4 2021-01-05 false 0001531048 Inari Medical, Inc. NARI 0001806431 Hykes Andrew C/O INARI MEDICAL, INC. 9 PARKER, SUITE 100 IRVINE CA 92618 false true false false Chief Operating Officer Common Stock 2021-01-05 4 S false 6486.00 77.8606 D 253655.00 D Common Stock 2021-01-05 4 S false 8514.00 78.8142 D 245141.00 D Common Stock 2021-01-05 4 S false 4600.00 80.0703 D 240541.00 D Common Stock 2021-01-05 4 S false 3175.00 81.2265 D 237366.00 D Common Stock 2021-01-05 4 S false 4215.00 81.8581 D 233151.00 D Common Stock 2021-01-05 4 S false 610.00 82.7831 D 232541.00 D Common Stock 1550.00 I By Child 1 Common Stock 1550.00 I By Child 2 Common Stock 1550.00 I By Child 3 Common Stock 1000.00 I By Spouse The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. This transaction was executed in multiple trades at prices ranging from $77.52 to $78.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $78.52 to $79.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $79.57 to $80.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $80.59 to $81.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. This transaction was executed in multiple trades at prices ranging from $81.59 to $82.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $82.66 to $83.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. /s/ Angela Ahmad, attorney-in-fact for 2021-01-06